Lovastatin Tablet
Product Images NDC 61442-142

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 61442-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carlsbad Technology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg 100ct

Lovastatin 10 mg oral tablets label from Carlsbad Technology, Inc. The label shows the drug name, strength, dosage form as tablets USP, and quantity of 100 tablets. It includes storage instructions (20° to 25°C, protect from light) and dispensing guidance. The label also displays the NDC number 61442-141-01 and a barcode.*

FDA Label Image

20mg 100ct

Lovastatin 20 mg oral tablets label from Carlsbad Technology, Inc. The label states the strength as 20 mg, quantity of 100 tablets, and includes storage instructions to keep the product at 20 to 25°C (68 to 77°F) in a tight, light-resistant container. The label also shows the NDC number 61442-142-01 and indicates Rx only.*

FDA Label Image

40mg 100ct

Label for Lovastatin tablets USP, 40 mg strength, manufactured and distributed by Carlsbad Technology, Inc. The label includes dosage form (tablet), quantity (100 tablets), storage instructions, and a barcode. The label notes the drug is prescription-only (Rx Only) and includes the NDC number 61442-143-01.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of lovastatin depicted as a two-dimensional molecular diagram showing its specific atomic composition and arrangement.*

FDA Label Image

Table I (Lov00 0004 02)

Data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' showing number of subjects, dosing of coadministered drug or grapefruit juice, dosing of Lovastatin, and AUC ratios comparing Lovastatin exposure with and without coadministered drugs.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without event over 6 years of follow-up. It compares Lovastatin and placebo groups, indicating a 37% risk reduction with Lovastatin (p < 0.001). The y-axis represents the proportion of participants without event, and the x-axis shows years of follow-up.*

FDA Label Image

Table Vii (Lov00 0005 04)

A table titled 'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' lists various interacting agents with prescribing recommendations for lovastatin. It includes strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice, with guidance such as contraindications, dosage limits, and avoidance advisories.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.